EntreMed Reviews

Recommend to a friend
Approve of CEO
EntreMed Chairman Michael M. Tarnow
Michael M. Tarnow
0 Ratings

EntreMed Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.entremed.com
Headquarters Rockville, MD
Size 6 to 15 Employees
Founded Unknown
Type Company - Public (ENMD)
Industry Biotech & Pharmaceuticals
Revenue Less than $1 million (USD) per year

EntreMed wants to get in between cancer and the blood vessels that feed it. The biotech pharmaceutical company develops drugs that inhibit angiogenesis, or the growth of new blood vessels. Its lead candidate, ENMD-2076, inhibits aurora kinases which regulate cell division and are linked to several cancers. The company has several other product candidates in its pipeline. EntreMed receives royalties from sales of Thalomid, a multiple myeloma therapy marketed by EntreMed's minority shareholder, Celgene.

Work at EntreMed? Share Your Experiences


Click to Rate